Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTBEAM-U01 Substudy 01C: Patritumab deruxtecan in pediatric relapsed or refractory solid tumors
2024-518771-66-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 23
01
Overview
Phase 2, open-label, single-arm trial of patritumab deruxtecan in rhabdomyosarcoma (RMS) and hepatoblastoma, sponsored by Merck & Co. Primary endpoints: Part 1: Percentage of participants who experience dose-limiting toxicities (DLTs), Part 1: Percentage of participants who experience an adverse event (AE) and 11 more. Planned start Jul 2025; status: authorised.
02
Drugs
patritumab deruxtecan
03
Conditions
rhabdomyosarcoma (RMS)hepatoblastoma
Beyond the preview
Go deeper on 2024-518771-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518771-66-00.